Fostemsavir Decreases the Levels of Anti-gp120 CD4-Induced Antibodies in Heavily Treatment-Experienced People With HIV
The Journal of Infectious Diseases · 2026
DOI: 10.1093/infdis/jiaf461 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2026. Verfasst von Mehdi Benlarbi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Axe immunopathologie, Montréal, Quebec, Canada. Hauptthemen laut MEDLINE: HIV Infections, HIV Envelope Protein gp120, Anti-HIV Agents, Organophosphates. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Fonds de Recherche du Québec-Santé, NIH HHS, ViiV.
Abstract (Originalsprache)
Background
Heavily treatment-experienced (HTE) people with HIV (PWH) have limited antiretroviral therapy (ART) treatment options, putting them at greater risk of unfavorable human immunodeficiency virus 1 (HIV-1) disease progression. Fostemsavir (BMS-663068) efficiently suppressed viremia and increased CD4 count when combined with other antiretrovirals in HTE PWH. Its active metabolite, temsavir (BMS-626529, GSK2616713), binds a conserved pocket within the envelope glycoprotein (Env) CD4 binding site and prevents CD4-induced conformational changes. Temsavir effect on Env conformation profoundly alters its glycosylation and cleavage, thereby modifying its antigenicity and reducing gp120 shedding. Here we evaluated if fostemsavir treatment in PWH modulated the levels of nonneutralizing gp120 CD4-induced (CD4i) antibodies (Abs) associated with CD4 depletion in vitro and in PWH.
Methods
We measured the levels of anti-gp120 CD4i Abs in plasma samples taken before and after fostemsavir treatment in HTE participants from the BRIGHTE trial and the PRESTIGIO registry and compared them to those of a control ART-treated group from the SAILING trial.
Results
We observed a significant decline of anti-gp120 CD4i Abs in the 2 fostemsavir-treated HTE groups, but not in the control group. Moreover, this effect was unique to anti-gp120 CD4i Abs, as no significant changes were observed in the levels of antibodies targeting Gag. Functionally, this decline in CD4i Abs was associated with a reduced capacity of plasma to recognize and eliminate uninfected primary CD4+ T cells coated with soluble gp120.
Conclusions
Altogether, fostemsavir may provide additional immune benefits to PWH, beyond blocking viral entry, by reducing anti-gp120 CD4i Abs levels. Clinical Trials Registration NCT04098315, NCT01231516, and NCT02362503.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Axe immunopathologie, Montréal, Quebec, Canada.
- Département de Microbiologie, Infectiologie, et Immunologie, Université de Montréal, Montréal, Quebec, Canada.
- Infectious Diseases, Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele Scientific Institute, Milan, Italy.
- Infectious Disease Division, Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA.
- ViiV Healthcare, London, United Kingdom.
- Department of Medicine, Faculty of Medicine, Centre Hospitalier de l'Université de Montréal, Montréal, Quebec, Canada.
ORCID-Profile: Jonathan Richard, Tommaso Clemente, Andrew Clark
Förderung
- Fonds de Recherche du Québec-Santé
- NIH HHS
- ViiV
- NIAID NIH HHS
- CIHR
- Canada Foundation for Innovation
- Canadian Institutes of Health Research
- National Institutes of Health
Zitieren
APA
Benlarbi, M., Richard, J., Clemente, T., Bourassa, C., Tolbert, W. D., Prakash, M., Chandravanshi, M., Clark, A., Pazgier, M., Durand, M., Castagna, A., & Finzi, A. (2026). Fostemsavir Decreases the Levels of Anti-gp120 CD4-Induced Antibodies in Heavily Treatment-Experienced People With HIV. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiaf461
Vancouver
Benlarbi M, Richard J, Clemente T, Bourassa C, Tolbert WD, Prakash M, et al. Fostemsavir Decreases the Levels of Anti-gp120 CD4-Induced Antibodies in Heavily Treatment-Experienced People With HIV. The Journal of Infectious Diseases. 2026. doi:10.1093/infdis/jiaf461
BibTeX
@article{Benlarbi2026,
author = {Benlarbi, Mehdi and Richard, Jonathan and Clemente, Tommaso and Bourassa, Catherine and Tolbert, William D and Prakash, Manyu and Chandravanshi, Monika and Clark, Andrew and Pazgier, Marzena and Durand, Madeleine and Castagna, Antonella and Finzi, Andrés},
title = {Fostemsavir Decreases the Levels of Anti-gp120 CD4-Induced Antibodies in Heavily Treatment-Experienced People With HIV},
journal = {The Journal of Infectious Diseases},
year = {2026},
doi = {10.1093/infdis/jiaf461}
}
EUVIMED